Screening Blood tests

DIAGNOSTIC_TEST2 trials

Sponsors

Code Pharma, Dana-Farber Cancer Institute

Conditions

COVID-19PDACPDAC - Pancreatic Ductal AdenocarcinomaPancreatic CancerPancreatic Ductal AdenocarcinomaPancreatic Neoplasm

Early Phase 1

Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals

RecruitingNCT06122896

Dana-Farber Cancer InstitutePancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Neoplasm +2

Start: 2023-11-21End: 2041-10-31Target: 5000Updated: 2025-06-03

Phase 2

Phase IIa Randomized Placebo Controlled Clinical Study of Codivir in Hospitalized Patients with Moderate COVID-19

RecruitingNCT05218356

Code PharmaCOVID-19

Start: 2022-01-20End: 2025-07-20Target: 130Updated: 2024-10-02